MétaCan
Menu
Back to cohort

Mutant IDH (mIDH) inhibitors, ivosidenib or enasidenib, with azacitidine (AZA) in patients with acute myeloid leukemia (AML).

2018· article· en· W2892126810 on OpenAlexaff
Courtney D. DiNardo, Anthony S. Stein, Eytan M. Stein, Amir T. Fathi, Andre C. Schuh, Pau Montesinos Fernández, Olatoyosi Odenike, Hagop M. Kantarjian, Richard M. Stone, Robert H. Collins, Giovanni Martinelli, Montserrat Arnán, Bin Wu, Daniel O. Koralek, Jason Van Oostendorp, Jing Gong, Kyle J. MacBeth, Paresh Vyas

Bibliographic record

VenueJournal of Clinical Oncology · 2018
Typearticle
Languageen
FieldMedicine
TopicMyeloproliferative Neoplasms: Diagnosis and Treatment
Canadian institutionsPrincess Margaret Cancer CentreUniversity Health Network
Fundersnot available
KeywordsMedicineNauseaAzacitidineInternal medicineGastroenterologyNeutropeniaFebrile neutropeniaMyeloid leukemiaToxicity

Abstract

fetched live from OpenAlex

7042 Background: Ivosidenib (IVO; AG-120) and enasidenib (ENA; AG-221) are oral inhibitors of mIDH1 and mIDH2 proteins. In vitro, mIDH inhibitor + AZA combinations enhance cell differentiation and apoptosis. We report results of an ongoing phase 1b/2 study of mIDH inhibitors + AZA in patients (pts) with newly diagnosed (ND) AML (NCT02677922). Methods: Adult pts with mIDH ND-AML ineligible for intensive treatment (Tx) receive continuous IVO (mIDH1) 500 mg or ENA (mIDH2) 100 or 200 mg QD, plus SC AZA 75 mg/m2 x 7d, in repeated 28d cycles. Response is defined by IWG 2003 AML criteria. Results: At data cutoff (Sep 1, 2017) 17 pts had received IVO 500 mg (n = 11) or ENA 100 mg (3) or 200 mg (3) + AZA in the phase 1b portion of the study; 11 were ongoing. IVO: Median age was 76 yrs. Median number of Tx cycles was 3 (range 1-13).Three pts discontinued Tx, 2 due to progressive disease (PD).AEs in ≥4 pts (any grade) were nausea (n = 8), constipation (6), fatigue (5) and diarrhea (4). Grade 3-4 hematological AEs (Table) occurred at similar frequency to what has been reported for AZA alone. Serious AEs in > 1 pt were pneumonia, febrile neutropenia (n = 2 each). Eight of 11 pts responded, including 4 complete remissions (CRs). ENA:Median age was 68 yrs. Median number of Tx cycles was 9 (1-13). Three pts discontinued Tx, 2 due to PD. Most common AEs (any grade) were nausea and hyperbilirubinemia (n = 4 each). Serious AEs in > 1 pt were pyrexia, bilirubin increase, pneumonia (n = 2 each). Four of 6 pts responded, including 2 CRs. Conclusions: mIDH inhibitor + AZA regimens were generally well tolerated in pts with ND-AML. Most AEs were grade 1-2 GI events and ENA-related indirect bilirubin elevations due to off-target UGT1A1 inhibition. Response rates are encouraging. Phase 1b enrollment completed in late 2017; updated data for all 23 IVO and 6 ENA pts will be presented, as well as longitudinal changes in mIDH variant allele frequencies. Enrollment continues in the phase 2 portion of this study (ENA + AZA) and the phase 3 AGILE study of IVO + AZA (NCT03173248). Clinical trial information: NCT02677922.Grade 3-4 hematological AEs. IVO 500 mg + AZA (n = 11) ENA 100 mg + AZA (n = 3) ENA 200 mg + AZA (n = 3) n Thrombocytopenia 1 0 1 Anemia 2 0 1 Febrile neutropenia 2 0 1 Neutropenia 1 0 2 Lymphocyte decrease 0 0 1 WBC decrease 0 0 1

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Non-randomized trial · Consensus signal: none
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.001
Threshold uncertainty score0.004

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.001
Insufficient payload (model declined to judge)0.0010.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.046
GPT teacher head0.387
Teacher spread0.340 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNon-randomized trial
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations32
Published2018
Admission routes1
Has abstractyes

Explore more

Same venueJournal of Clinical OncologySame topicMyeloproliferative Neoplasms: Diagnosis and TreatmentFrench-language works237,207